Author: Ken Dropiewski

Mesoblast Reports Financial Results and Operational Highlights for Fiscal Year Ended June 30, 2022

At June 30, 2022, cash-on-hand was US$60.4 million with pro-forma US$105.5 million after raising gross proceeds of US$45 million via a private placement in August, 2022 Up to an additional US$40 million available from existing facilities subject to certain milestones Net operating spend of US$65.8 million for the 12 months […]

Medtronic completes acquisition of Affera

Acquisition adds mapping and navigation platform to company’s cardiac ablation portfolio and brings an integrated system of diagnostic and therapeutic tools to address a broad spectrum of arrhythmias DUBLIN, Aug. 30, 2022 /PRNewswire/ — Medtronic plc (NYSE:MDT), a global leader in healthcare technology, today announced that it has completed the acquisition of […]

LifeTech Scientific Corporation (1302.HK) Announces 2022 Interim Results

Revenue increased by 20.4%, net profit attributable to owners of the Company increased by 34.4% after excluding certain non-recurring items SHENZHEN, China, Aug. 30, 2022 /PRNewswire/ — LifeTech Scientific Corporation (the “Company” or “Lifetech”), a leading company specialized in minimally invasive interventional medical devices for cardio-cerebrovascular and peripheral vascular diseases announces the unaudited consolidated results of the Company and […]

BioSig Strengthens Marketing and Sales Teams, Appoints National Account Executives to Scale Commercial Growth

Company increases sales efforts and strategy, adds new National Account Executives to accelerate commercial growth Strengthens marketing team with new marketing and communications programs highlighting competitive market advantage BioSig Technologies, Inc. (NASDAQ: BSGM) (“BioSig” or the “Company”), a medical technology company advancing electrophysiology workflow by delivering greater intracardiac signal fidelity […]

Hello Heart Announces a Groundbreaking Feature for Managing Cholesterol, Becoming the First and Only Digital Therapeutic to Tackle Whole-Heart Health

As we approach National Cholesterol Education Month, My Cholesterol will provide millions of users with clarity on their cholesterol and triglycerides trends through personalized, gender-specific insights and coaching MENLO PARK, Calif.–(BUSINESS WIRE)–Hello Heart, the only digital therapeutic that focuses exclusively on heart health, today announced a new cholesterol management feature, designed to […]

Ambrx Biopharma Inc. Reports 1H 2022 Financial Results and Provides Corporate Update

– Appointed Kate Hermans as Interim Chief Executive Officer – SAN DIEGO–(BUSINESS WIRE)–​Ambrx Biopharma Inc., or Ambrx, (NYSE: AMAM), a clinical stage biopharmaceutical company using an expanded genetic code technology platform to create Engineered Precision Biologics (EPBs), today provided a corporate update and reported financial results for the first half […]

CereVasc Announces First Patient Treated in U.S. Pilot Trial Evaluating the eShunt System in Patients with Normal Pressure Hydrocephalus

BOSTON, Aug. 29, 2022 /PRNewswire/ — CereVasc, Inc., a privately held, clinical-stage, medical device company developing novel, minimally invasive treatments for neurological diseases, announced completion of the first eShunt® procedure in the United States. The study, ‘US Pilot Study of the CereVasc eShunt System in Normal Pressure Hydrocephalus (NPH)’, is being conducted under an investigational device […]

New Data Show Abbott’s HeartMate 3™ Heart Pump Extends Life Beyond Five Years for Advanced Heart Failure Patients

  New data from the MOMENTUM 3 study showed for the first time that a heart pump can extend survival to five years and beyond for advanced heart failure patients Prior data1 have shown survival for advanced heart failure patients who don’t receive either a heart pump or heart transplant is […]

NEW AMGEN DATA AT ESC 2022 SHOW LONG-TERM LDL-C LOWERING WITH REPATHA® (EVOLOCUMAB) WAS WELL-TOLERATED FOR MORE THAN 8 YEARS

Earlier Treatment With Repatha Resulted in a Lower Incidence of Major CV Events, Including CV Death 80% of Patients Achieved Guideline Directed LDL-C Levels of <55 mg/dL at Week 12 Data Presented at ESC 2022 and Simultaneously Published in Circulation THOUSAND OAKS, Calif., Aug. 29, 2022 /PRNewswire/ — Amgen (NASDAQ:AMGN) today presented new […]